Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04529772




Registration number
NCT04529772
Ethics application status
Date submitted
25/08/2020
Date registered
28/08/2020

Titles & IDs
Public title
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Scientific title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects =75 Years With Previously Untreated Non-GCB DLBCL
Secondary ID [1] 0 0
2019-001755-39
Secondary ID [2] 0 0
D8227C00001
Universal Trial Number (UTN)
Trial acronym
ESCALADE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diffuse Large B-Cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - acalabrutinib
Treatment: Drugs - placebo
Treatment: Drugs - Prednisone
Treatment: Drugs - Rituximab
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Vincristine
Treatment: Drugs - Doxorubicin

Experimental: acalabrutinib + R-CHOP - Acalabrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)

Placebo comparator: placebo + R-CHOP - Placebo plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)


Treatment: Drugs: acalabrutinib
Investigational Product

Treatment: Drugs: placebo
Placebo comparator

Treatment: Drugs: Prednisone
Investigational Product

Treatment: Drugs: Rituximab
Investigational Product

Treatment: Drugs: Cyclophosphamide
Investigational Product

Treatment: Drugs: Vincristine
Investigational Product

Treatment: Drugs: Doxorubicin
Investigational Product
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B
Timepoint [1] 0 0
at every single visit up to 60 months
Secondary outcome [1] 0 0
Investigator-assessed event-free survival (EFS) for NHL in Arm A compared to Arm B
Timepoint [1] 0 0
at every single visit up to 60 months
Secondary outcome [2] 0 0
Overall survival in Arm A compared to Arm B
Timepoint [2] 0 0
at every single visit up to 60 months
Secondary outcome [3] 0 0
Percentage of Participants Who Achieved a Complete Response (CR) per 2014 Lugano Classification for NHL
Timepoint [3] 0 0
at every single visit up to 60 months

Eligibility
Key inclusion criteria
* Men and women, age =18 and =75 years
* Pathologically confirmed DLBCL, sufficient diagnostic material should be available to forward to a central laboratory for gene expression profiling and pathology review.
* No prior treatment for DLBCL
* Eastern Cooperative Oncology Group (ECOG) performance status of = 2.
* International Prognostic Index (IPI) score of 1 to 5
* Disease Stage II to IV by the Ann Arbor Classification
* Adequate organ and marrow function
* Agreement to use highly effective forms of contraception during the study and 12 months after the last dose of rituximab
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Evidence of severe or uncontrolled systemic diseases
* Known history of a bleeding diathesis (i.e., haemophilia, von Willebrand disease)
* History of stroke or intracranial haemorrhage in preceding 6 months.
* Known CNS lymphoma or leptomeningeal disease
* Known primary mediastinal lymphoma
* Known High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
* Prior history of indolent lymphoma or CLL
* History of or ongoing confirmed PML
* Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
* Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
* Uncontrolled active systemic fungal, bacterial, viral, or other infection
* Prior anthracycline use =150 mg/m2

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
5/02/2027
Actual
Sample size
Target
Accrual to date
Final
611
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Adelaide
Recruitment hospital [2] 0 0
Research Site - Camperdown
Recruitment hospital [3] 0 0
Research Site - Clayton
Recruitment hospital [4] 0 0
Research Site - Darlinghurst
Recruitment hospital [5] 0 0
Research Site - Heidelberg
Recruitment hospital [6] 0 0
Research Site - Hobart
Recruitment hospital [7] 0 0
Research Site - Kogarah
Recruitment hospital [8] 0 0
Research Site - Liverpool
Recruitment hospital [9] 0 0
Research Site - Nedlands
Recruitment hospital [10] 0 0
Research Site - Westmead
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
7000 - Hobart
Recruitment postcode(s) [7] 0 0
2217 - Kogarah
Recruitment postcode(s) [8] 0 0
2170 - Liverpool
Recruitment postcode(s) [9] 0 0
6009 - Nedlands
Recruitment postcode(s) [10] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
Austria
State/province [22] 0 0
Linz
Country [23] 0 0
Austria
State/province [23] 0 0
Salzburg
Country [24] 0 0
Austria
State/province [24] 0 0
Wels
Country [25] 0 0
Belgium
State/province [25] 0 0
Antwerpen
Country [26] 0 0
Belgium
State/province [26] 0 0
Brugge
Country [27] 0 0
Belgium
State/province [27] 0 0
La Louvière
Country [28] 0 0
Brazil
State/province [28] 0 0
Curitiba
Country [29] 0 0
Brazil
State/province [29] 0 0
Florianopolis
Country [30] 0 0
Brazil
State/province [30] 0 0
Goiania
Country [31] 0 0
Brazil
State/province [31] 0 0
Passo Fundo
Country [32] 0 0
Brazil
State/province [32] 0 0
Porto Alegre
Country [33] 0 0
Brazil
State/province [33] 0 0
Ribeirão Preto
Country [34] 0 0
Brazil
State/province [34] 0 0
Rio de Janeiro
Country [35] 0 0
Brazil
State/province [35] 0 0
Sao Paulo
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo
Country [37] 0 0
Canada
State/province [37] 0 0
British Columbia
Country [38] 0 0
Canada
State/province [38] 0 0
CA
Country [39] 0 0
Canada
State/province [39] 0 0
Manitoba
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Canada
State/province [41] 0 0
Quebec
Country [42] 0 0
Canada
State/province [42] 0 0
Ottawa
Country [43] 0 0
China
State/province [43] 0 0
Beijing
Country [44] 0 0
China
State/province [44] 0 0
Changchun
Country [45] 0 0
China
State/province [45] 0 0
Chengdu
Country [46] 0 0
China
State/province [46] 0 0
Guangzhou
Country [47] 0 0
China
State/province [47] 0 0
Hangzhou
Country [48] 0 0
China
State/province [48] 0 0
Harbin
Country [49] 0 0
China
State/province [49] 0 0
Jinan
Country [50] 0 0
China
State/province [50] 0 0
Luoyang
Country [51] 0 0
China
State/province [51] 0 0
Nanchang
Country [52] 0 0
China
State/province [52] 0 0
Nanning
Country [53] 0 0
China
State/province [53] 0 0
Shanghai
Country [54] 0 0
China
State/province [54] 0 0
Shenyang
Country [55] 0 0
China
State/province [55] 0 0
Shijiazhuang
Country [56] 0 0
China
State/province [56] 0 0
Suzhou
Country [57] 0 0
China
State/province [57] 0 0
Tianjin
Country [58] 0 0
China
State/province [58] 0 0
Wuhan
Country [59] 0 0
China
State/province [59] 0 0
Xiamen
Country [60] 0 0
China
State/province [60] 0 0
Zhengzhou
Country [61] 0 0
Czechia
State/province [61] 0 0
Brno
Country [62] 0 0
Czechia
State/province [62] 0 0
Hradec Kralove
Country [63] 0 0
Czechia
State/province [63] 0 0
Ostrava - Poruba
Country [64] 0 0
Czechia
State/province [64] 0 0
Plzen
Country [65] 0 0
Czechia
State/province [65] 0 0
Praha 10
Country [66] 0 0
Czechia
State/province [66] 0 0
Praha 2
Country [67] 0 0
France
State/province [67] 0 0
Brest
Country [68] 0 0
France
State/province [68] 0 0
Caen Cedex 9
Country [69] 0 0
France
State/province [69] 0 0
Marseille
Country [70] 0 0
France
State/province [70] 0 0
Montpellier
Country [71] 0 0
France
State/province [71] 0 0
Nantes
Country [72] 0 0
France
State/province [72] 0 0
Pessac
Country [73] 0 0
France
State/province [73] 0 0
Pierre Benite
Country [74] 0 0
France
State/province [74] 0 0
Rennes Cedex 9
Country [75] 0 0
France
State/province [75] 0 0
Toulouse
Country [76] 0 0
Germany
State/province [76] 0 0
Bamberg
Country [77] 0 0
Germany
State/province [77] 0 0
Berlin
Country [78] 0 0
Germany
State/province [78] 0 0
Dresden
Country [79] 0 0
Germany
State/province [79] 0 0
Homburg
Country [80] 0 0
Germany
State/province [80] 0 0
Neumünster
Country [81] 0 0
India
State/province [81] 0 0
Bangalore
Country [82] 0 0
India
State/province [82] 0 0
Delhi
Country [83] 0 0
India
State/province [83] 0 0
Kochi
Country [84] 0 0
India
State/province [84] 0 0
Mumbai
Country [85] 0 0
India
State/province [85] 0 0
Nashik
Country [86] 0 0
India
State/province [86] 0 0
Pune
Country [87] 0 0
Israel
State/province [87] 0 0
Afula
Country [88] 0 0
Israel
State/province [88] 0 0
Ashdod
Country [89] 0 0
Israel
State/province [89] 0 0
Beer Sheba
Country [90] 0 0
Israel
State/province [90] 0 0
Haifa
Country [91] 0 0
Israel
State/province [91] 0 0
Holon
Country [92] 0 0
Israel
State/province [92] 0 0
Jerusalem
Country [93] 0 0
Israel
State/province [93] 0 0
Nahariya
Country [94] 0 0
Israel
State/province [94] 0 0
Petah Tikva
Country [95] 0 0
Israel
State/province [95] 0 0
Ramat Gan
Country [96] 0 0
Israel
State/province [96] 0 0
Tel Aviv
Country [97] 0 0
Israel
State/province [97] 0 0
Zerifin
Country [98] 0 0
Italy
State/province [98] 0 0
Bari
Country [99] 0 0
Italy
State/province [99] 0 0
Bergamo
Country [100] 0 0
Italy
State/province [100] 0 0
Bologna
Country [101] 0 0
Italy
State/province [101] 0 0
Firenze
Country [102] 0 0
Italy
State/province [102] 0 0
Genova
Country [103] 0 0
Italy
State/province [103] 0 0
Meldola
Country [104] 0 0
Italy
State/province [104] 0 0
Milano
Country [105] 0 0
Italy
State/province [105] 0 0
Milan
Country [106] 0 0
Italy
State/province [106] 0 0
Novara
Country [107] 0 0
Italy
State/province [107] 0 0
Palermo
Country [108] 0 0
Italy
State/province [108] 0 0
Pavia
Country [109] 0 0
Italy
State/province [109] 0 0
Pisa
Country [110] 0 0
Italy
State/province [110] 0 0
Ravenna
Country [111] 0 0
Italy
State/province [111] 0 0
Reggio Emilia
Country [112] 0 0
Italy
State/province [112] 0 0
Roma
Country [113] 0 0
Italy
State/province [113] 0 0
Siena
Country [114] 0 0
Italy
State/province [114] 0 0
Torino
Country [115] 0 0
Italy
State/province [115] 0 0
Tricase
Country [116] 0 0
Italy
State/province [116] 0 0
Venezia
Country [117] 0 0
Japan
State/province [117] 0 0
Chiba-shi
Country [118] 0 0
Japan
State/province [118] 0 0
Chuo-ku
Country [119] 0 0
Japan
State/province [119] 0 0
Fukuoka-shi
Country [120] 0 0
Japan
State/province [120] 0 0
Itabashi-ku
Country [121] 0 0
Japan
State/province [121] 0 0
Kahoku-gun
Country [122] 0 0
Japan
State/province [122] 0 0
Kashiwa
Country [123] 0 0
Japan
State/province [123] 0 0
Kobe-shi
Country [124] 0 0
Japan
State/province [124] 0 0
Koto-ku
Country [125] 0 0
Japan
State/province [125] 0 0
Kumamoto-shi
Country [126] 0 0
Japan
State/province [126] 0 0
Kyoto-city
Country [127] 0 0
Japan
State/province [127] 0 0
Matsuyama-shi
Country [128] 0 0
Japan
State/province [128] 0 0
Nagasaki-shi
Country [129] 0 0
Japan
State/province [129] 0 0
Nagoya-shi
Country [130] 0 0
Japan
State/province [130] 0 0
Niigata-shi
Country [131] 0 0
Japan
State/province [131] 0 0
Okayama-shi
Country [132] 0 0
Japan
State/province [132] 0 0
Osaka-shi
Country [133] 0 0
Japan
State/province [133] 0 0
Sapporo-shi
Country [134] 0 0
Japan
State/province [134] 0 0
Sendai-shi
Country [135] 0 0
Japan
State/province [135] 0 0
Shimotsuke-shi
Country [136] 0 0
Japan
State/province [136] 0 0
Tsu-shi
Country [137] 0 0
Korea, Republic of
State/province [137] 0 0
Busan
Country [138] 0 0
Korea, Republic of
State/province [138] 0 0
Goyang-si
Country [139] 0 0
Korea, Republic of
State/province [139] 0 0
Jeonju-si
Country [140] 0 0
Korea, Republic of
State/province [140] 0 0
Seoul
Country [141] 0 0
Korea, Republic of
State/province [141] 0 0
Suwon-si
Country [142] 0 0
Mexico
State/province [142] 0 0
Chihuahua
Country [143] 0 0
Mexico
State/province [143] 0 0
Monterrey
Country [144] 0 0
Poland
State/province [144] 0 0
Gdansk
Country [145] 0 0
Poland
State/province [145] 0 0
Kraków
Country [146] 0 0
Poland
State/province [146] 0 0
Lublin
Country [147] 0 0
Poland
State/province [147] 0 0
Warszawa
Country [148] 0 0
Poland
State/province [148] 0 0
Wroclaw
Country [149] 0 0
Poland
State/province [149] 0 0
Lódz
Country [150] 0 0
Portugal
State/province [150] 0 0
Braga
Country [151] 0 0
Portugal
State/province [151] 0 0
Lisboa
Country [152] 0 0
Portugal
State/province [152] 0 0
Matosinhos
Country [153] 0 0
Portugal
State/province [153] 0 0
Porto
Country [154] 0 0
Portugal
State/province [154] 0 0
Vila Nova de Gaia
Country [155] 0 0
Russian Federation
State/province [155] 0 0
Chelyabinsk
Country [156] 0 0
Russian Federation
State/province [156] 0 0
Moscow
Country [157] 0 0
Russian Federation
State/province [157] 0 0
Saint Petersburg
Country [158] 0 0
Russian Federation
State/province [158] 0 0
St. Petersburg
Country [159] 0 0
Spain
State/province [159] 0 0
Alcalá De Henares
Country [160] 0 0
Spain
State/province [160] 0 0
Barcelona
Country [161] 0 0
Spain
State/province [161] 0 0
Gijón
Country [162] 0 0
Spain
State/province [162] 0 0
L'Hospitalet de Llobregat
Country [163] 0 0
Spain
State/province [163] 0 0
Madrid
Country [164] 0 0
Spain
State/province [164] 0 0
Palma
Country [165] 0 0
Spain
State/province [165] 0 0
Pamplona
Country [166] 0 0
Spain
State/province [166] 0 0
Pozuelo de Alarcón
Country [167] 0 0
Spain
State/province [167] 0 0
Salamanca
Country [168] 0 0
Spain
State/province [168] 0 0
Sevilla
Country [169] 0 0
Spain
State/province [169] 0 0
Valencia
Country [170] 0 0
Taiwan
State/province [170] 0 0
Kaohsiung
Country [171] 0 0
Taiwan
State/province [171] 0 0
Tainan
Country [172] 0 0
Taiwan
State/province [172] 0 0
Taipei 112
Country [173] 0 0
Taiwan
State/province [173] 0 0
Taipei
Country [174] 0 0
Taiwan
State/province [174] 0 0
Taoyuan City
Country [175] 0 0
Turkey
State/province [175] 0 0
Ankara
Country [176] 0 0
Turkey
State/province [176] 0 0
Balcova
Country [177] 0 0
Turkey
State/province [177] 0 0
Edirne
Country [178] 0 0
Turkey
State/province [178] 0 0
Izmir
Country [179] 0 0
Turkey
State/province [179] 0 0
Kayseri
Country [180] 0 0
Turkey
State/province [180] 0 0
Mersin
Country [181] 0 0
Turkey
State/province [181] 0 0
Samsun
Country [182] 0 0
Turkey
State/province [182] 0 0
Trabzon
Country [183] 0 0
Ukraine
State/province [183] 0 0
Cherkasy
Country [184] 0 0
Ukraine
State/province [184] 0 0
Khmelnytskyi
Country [185] 0 0
Ukraine
State/province [185] 0 0
Kyiv
Country [186] 0 0
Ukraine
State/province [186] 0 0
Lviv
Country [187] 0 0
Ukraine
State/province [187] 0 0
Mykolayiv
Country [188] 0 0
Ukraine
State/province [188] 0 0
Zaporizhzhia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Acerta Pharma BV
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
AstraZeneca
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP)
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Available to whom?
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://astrazenecagroup-dt.pharmacm.com/DT/Home


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04529772